Literature DB >> 19620404

A truncated CFTR protein rescues endogenous DeltaF508-CFTR and corrects chloride transport in mice.

Estelle Cormet-Boyaka1, Jeong S Hong, Bakhram K Berdiev, James A Fortenberry, Jessica Rennolds, J P Clancy, Dale J Benos, Prosper N Boyaka, Eric J Sorscher.   

Abstract

Cystic fibrosis (CF) is most frequently associated with deletion of phenylalanine at position 508 (DeltaF508) in the CF transmembrane conductance regulator (CFTR) protein. The DeltaF508-CFTR mutant protein exhibits a folding defect that affects its processing and impairs chloride-channel function. This study aimed to determine whether CFTR fragments approximately half the size of wild-type CFTR and complementary to the portion of CFTR bearing the mutation can specifically rescue the processing of endogenous DeltaF508-CFTR in vivo. cDNA encoding CFTR fragments were delivered to human airway epithelial cells and mice harboring endogenous DeltaF508-CFTR. Delivery of small CFTR fragments, which do not act as chloride channels by themselves, rescue DeltaF508-CFTR. Therefore, we can speculate that the presence of the CFTR fragment, which does not harbor a mutation, might facilitate intermolecular interactions. The rescue of CFTR was evident by the restoration of chloride transport in human CFBE41o- bronchial epithelial cells expressing DeltaF508-CFTR in vitro. More important, nasal administration of an adenovirus expressing a complementary CFTR fragment restored some degree of CFTR activity in the nasal airways of DeltaF508 homozygous mice in vivo. These findings identify complementary protein fragments as a viable in vivo approach for correcting disease-causing misfolding of plasma membrane proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620404      PMCID: PMC2775001          DOI: 10.1096/fj.08-127878

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  45 in total

1.  Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.

Authors:  C R Brown; L Q Hong-Brown; J Biwersi; A S Verkman; W J Welch
Journal:  Cell Stress Chaperones       Date:  1996-06       Impact factor: 3.667

2.  A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction.

Authors:  J R Dorin; R Farley; S Webb; S N Smith; E Farini; S J Delaney; B J Wainwright; E W Alton; D J Porteous
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

3.  Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties.

Authors:  D N Sheppard; D P Rich; L S Ostedgaard; R J Gregory; A E Smith; M J Welsh
Journal:  Nature       Date:  1993-03-11       Impact factor: 49.962

4.  Multiple proteolytic systems, including the proteasome, contribute to CFTR processing.

Authors:  T J Jensen; M A Loo; S Pind; D B Williams; A L Goldberg; J R Riordan
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

5.  The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells.

Authors:  G L Lukacs; X B Chang; C Bear; N Kartner; A Mohamed; J R Riordan; S Grinstein
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

6.  Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium.

Authors:  A Scaria; J A St George; C Jiang; J M Kaplan; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

7.  Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation.

Authors:  S Sato; C L Ward; M E Krouse; J J Wine; R R Kopito
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

8.  Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal.

Authors:  L S Prince; K Peter; S R Hatton; L Zaliauskiene; L F Cotlin; J P Clancy; R B Marchase; J F Collawn
Journal:  J Biol Chem       Date:  1999-02-05       Impact factor: 5.157

Review 9.  Biosynthesis and degradation of CFTR.

Authors:  R R Kopito
Journal:  Physiol Rev       Date:  1999-01       Impact factor: 37.312

10.  Adenovirus-mediated gene transfer to ciliated airway epithelia requires prolonged incubation time.

Authors:  J Zabner; B G Zeiher; E Friedman; M J Welsh
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  9 in total

Review 1.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

2.  Functional rescue of a misfolded eukaryotic ATP-binding cassette transporter by domain replacement.

Authors:  Raymond J Louie; Silvere Pagant; Ji-Young Youn; John J Halliday; Gregory Huyer; Susan Michaelis; Elizabeth A Miller
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

3.  Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.

Authors:  Wilson Yu; Patrick Kim Chiaw; Christine E Bear
Journal:  J Biol Chem       Date:  2011-05-21       Impact factor: 5.157

4.  Transcomplementation by a truncation mutant of cystic fibrosis transmembrane conductance regulator (CFTR) enhances ΔF508 processing through a biomolecular interaction.

Authors:  Liudmila Cebotaru; Owen Woodward; Valeriu Cebotaru; William B Guggino
Journal:  J Biol Chem       Date:  2013-03-05       Impact factor: 5.157

5.  Positional effects of premature termination codons on the biochemical and biophysical properties of CFTR.

Authors:  Jiunn-Tyng Yeh; Tzyh-Chang Hwang
Journal:  J Physiol       Date:  2019-11-02       Impact factor: 5.182

6.  Dysferlin-peptides reallocate mutated dysferlin thereby restoring function.

Authors:  Verena Schoewel; Andreas Marg; Severine Kunz; Tim Overkamp; Romy Siegert Carrazedo; Ute Zacharias; Peter T Daniel; Simone Spuler
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

7.  Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitors.

Authors:  Martina Wilke; Alice Bot; Huub Jorna; Bob J Scholte; Hugo R de Jonge
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

8.  CFTR mutations altering CFTR fragmentation.

Authors:  Kendra Tosoni; Michelle Stobbart; Diane M Cassidy; Andrea Venerando; Mario A Pagano; Simão Luz; Margarida D Amaral; Karl Kunzelmann; Lorenzo A Pinna; Carlos M Farinha; Anil Mehta
Journal:  Biochem J       Date:  2013-01-01       Impact factor: 3.857

9.  Targeted Integration of a Super-Exon into the CFTR Locus Leads to Functional Correction of a Cystic Fibrosis Cell Line Model.

Authors:  Christien Bednarski; Katja Tomczak; Beate Vom Hövel; Wolf-Michael Weber; Toni Cathomen
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.